Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 4
2017 6
2019 5
2020 8
2021 11
2022 5
2023 5
2024 6
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Martínez-Sáez O, Chic N, Pascual T, Adamo B, Vidal M, González-Farré B, Sanfeliu E, Schettini F, Conte B, Brasó-Maristany F, Rodríguez A, Martínez D, Galván P, Rodríguez AB, Martinez A, Muñoz M, Prat A. Martínez-Sáez O, et al. Breast Cancer Res. 2020 May 13;22(1):45. doi: 10.1186/s13058-020-01284-9. Breast Cancer Res. 2020. PMID: 32404150 Free PMC article.
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.
Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavilá J, Barrios CH, Lluch A, Martín M, Locci M, De Placido S, Prat A. Schettini F, et al. NPJ Breast Cancer. 2021 Jan 4;7(1):1. doi: 10.1038/s41523-020-00208-2. NPJ Breast Cancer. 2021. PMID: 33397968 Free PMC article.
Hormone receptor-positive early breast cancer in young women: A comprehensive review.
Walbaum B, García-Fructuoso I, Martínez-Sáez O, Schettini F, Sánchez C, Acevedo F, Chic N, Muñoz-Carrillo J, Adamo B, Muñoz M, Partridge AH, Bellet M, Brasó-Maristany F, Prat A, Vidal M. Walbaum B, et al. Cancer Treat Rev. 2024 Sep;129:102804. doi: 10.1016/j.ctrv.2024.102804. Epub 2024 Jul 14. Cancer Treat Rev. 2024. PMID: 39084152 Review.
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
Fernandez-Martinez A, Pascual T, Singh B, Nuciforo P, Rashid NU, Ballman KV, Campbell JD, Hoadley KA, Spears PA, Pare L, Brasó-Maristany F, Chic N, Krop I, Partridge A, Cortés J, Llombart-Cussac A, Prat A, Perou CM, Carey LA. Fernandez-Martinez A, et al. JAMA Oncol. 2023 Apr 1;9(4):490-499. doi: 10.1001/jamaoncol.2022.6288. JAMA Oncol. 2023. PMID: 36602784 Free PMC article. Clinical Trial.
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study.
Schettini F, Brasó-Maristany F, Pascual T, Lorman-Carbó N, Nucera S, Bergamino M, Galván P, Conte B, Seguí E, García Fructuoso I, Gómez Bravo R, Rodríguez AB, Martínez-Sáez O, Chic N, Vidal M, Adamo B, González-Farre B, Sanfeliu E, Cebrecos I, Mensión E, Oses G, Locci M, Mollà M, Ganau S, Jares P, Vidal-Sicart S, Muñoz M, Prat A. Schettini F, et al. ESMO Open. 2024 Dec;9(12):103989. doi: 10.1016/j.esmoop.2024.103989. Epub 2024 Nov 27. ESMO Open. 2024. PMID: 39608304 Free PMC article.
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Prat A, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernández PL, Galván P, Chic N, González Farré X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montaño A, Izarzugaza Y, Llombart-Cussac A, Bratos R, González Santiago S, Martínez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, López R, Céliz P, Ciruelos E, Villagrasa P, Gavilá J. Prat A, et al. Lancet Oncol. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838010 Clinical Trial.
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer.
Lorman-Carbó N, Martínez-Sáez O, Fernandez-Martinez A, Galván P, Chic N, Garcia-Fructuoso I, Rodríguez A, Gómez-Bravo R, Schettini F, Blasco P, Castillo O, González-Farré B, Adamo B, Vidal M, Muñoz M, Perou CM, Malumbres M, Gavilá J, Pascual T, Prat A, Brasó-Maristany F. Lorman-Carbó N, et al. Sci Rep. 2024 Jul 11;14(1):16030. doi: 10.1038/s41598-024-67126-2. Sci Rep. 2024. PMID: 38992220 Free PMC article.
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.
Conte B, Brasó-Maristany F, Hernández AR, Pascual T, Villacampa G, Schettini F, Vidal Losada MJ, Seguí E, Angelats L, Garcia-Fructuoso I, Gómez-Bravo R, Lorman-Carbó N, Paré L, Marín-Aguilera M, Martínez-Sáez O, Adamo B, Sanfeliu E, Fratini B, Falato C, Chic N, Vivancos A, Villagrasa P, Staaf J, Parker JS, Perou CM, Prat A. Conte B, et al. EBioMedicine. 2024 Apr;102:105043. doi: 10.1016/j.ebiom.2024.105043. Epub 2024 Mar 5. EBioMedicine. 2024. PMID: 38447275 Free PMC article.
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.
Pascual T, Fernandez-Martinez A, Agrawal Y, Pfefferle AD, Chic N, Brasó-Maristany F, Gonzàlez-Farré B, Paré L, Villacampa G, Saura C, Hernando C, Muñoz M, Galván P, Gonzàlez-Farré X, Oliveira M, Gil-Gil M, Ciruelos E, Villagrasa P, Gavilá J, Prat A, Perou CM. Pascual T, et al. NPJ Breast Cancer. 2024 Mar 6;10(1):20. doi: 10.1038/s41523-024-00625-7. NPJ Breast Cancer. 2024. PMID: 38448600 Free PMC article.
44 results